Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLK Allakos	$1.07 +0.5%	$1.28	$1.00 ▼ $5.64	$93.58M	0.82	1.28 million shs	130,480 shs
CMPS COMPASS Pathways	$8.45 +1.1%	$9.88	$5.01 ▼ $12.75	$523.39M	2.48	678,293 shs	112,407 shs
CNCE Concert Pharmaceuticals	$8.37	$8.37	$2.66 ▼ $8.55	$401.26M	0.52	2.97 million shs	N/A
LXRX Lexicon Pharmaceuticals	$1.68 -2.0%	$2.34	$0.92 ▼ $3.79	$412.45M	1.27	4.42 million shs	1.33 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLK Allakos	-0.93%	-1.85%	-21.48%	-10.17%	-76.81%
CMPS COMPASS Pathways	-0.24%	+0.48%	-6.90%	-4.68%	-6.70%
CNCE Concert Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
LXRX Lexicon Pharmaceuticals	+3.64%	-8.56%	-24.34%	+6.87%	-31.33%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLK Allakos	4.132 of 5 stars	3.1	3.0	0.0	4.7	0.6	3.3	1.3
CMPS COMPASS Pathways	1.526 of 5 stars	3.5	2.0	0.0	0.0	2.4	1.7	0.0
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	0.9842 of 5 stars	3.0	1.0	0.0	0.0	1.9	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLK Allakos	2.20	Hold	$1.83	72.14% Upside
CMPS COMPASS Pathways	3.00	Buy	$47.40	460.95% Upside
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	2.00	Hold	$5.00	198.51% Upside

Current Analyst Ratings

Latest ALLK, CNCE, CMPS, and LXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/23/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
4/18/2024	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
4/11/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
4/1/2024	CMPS COMPASS Pathways	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$30.00
3/1/2024	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLK Allakos	N/A	N/A	N/A	N/A	$1.93 per share	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$3.65 per share	N/A
CNCE Concert Pharmaceuticals	$32.58M	12.32	N/A	N/A	$3.24 per share	2.58
LXRX Lexicon Pharmaceuticals	$1.20M	343.71	N/A	N/A	$0.38 per share	4.41

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLK Allakos	-$185.70M	-$2.13	N/A	N/A	N/A	N/A	-80.23%	-62.03%	5/14/2024 (Estimated)
CMPS COMPASS Pathways	-$118.46M	-$2.39	N/A	N/A	N/A	N/A	-58.72%	-49.46%	5/9/2024 (Estimated)
CNCE Concert Pharmaceuticals	-$80.05M	-$3.21	N/A	N/A	N/A	N/A	-109.43%	-76.65%	N/A
LXRX Lexicon Pharmaceuticals	-$177.12M	-$0.80	N/A	N/A	N/A	-14,573.20%	-138.54%	-71.29%	5/7/2024 (Estimated)

Latest ALLK, CNCE, CMPS, and LXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/14/2024	Q4 2023	ALLK Allakos	-$0.53	-$0.71	-$0.18	-$0.71	N/A	N/A
3/11/2024	Q4 2023	LXRX Lexicon Pharmaceuticals	-$0.23	-$0.20	+$0.03	-$0.20	$0.68 million	$0.70 million
2/29/2024	Q4 2023	CMPS COMPASS Pathways	-$0.37	-$0.53	-$0.16	-$0.53	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLK Allakos	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLK Allakos	N/A	4.92	4.92
CMPS COMPASS Pathways	0.14	13.33	13.33
CNCE Concert Pharmaceuticals	N/A	9.03	9.03
LXRX Lexicon Pharmaceuticals	1.07	5.60	5.58

Ownership

Institutional Ownership

Company	Institutional Ownership
ALLK Allakos	84.64%
CMPS COMPASS Pathways	46.19%
CNCE Concert Pharmaceuticals	70.63%
LXRX Lexicon Pharmaceuticals	74.70%

Insider Ownership

Company	Insider Ownership
ALLK Allakos	28.07%
CMPS COMPASS Pathways	4.25%
CNCE Concert Pharmaceuticals	11.33%
LXRX Lexicon Pharmaceuticals	4.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLK Allakos	131	87.87 million	63.21 million	Optionable
CMPS COMPASS Pathways	186	61.94 million	59.31 million	Optionable
CNCE Concert Pharmaceuticals	64	47.94 million	42.51 million	Optionable
LXRX Lexicon Pharmaceuticals	285	246.24 million	235.16 million	Optionable

ALLK, CNCE, CMPS, and LXRX Headlines

Source	Headline
	Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Hold Rating from Needham & Company LLC marketbeat.com - April 23 at 8:20 AM
	Lexicon Pharmaceuticals to Host 2024 Investor Day globenewswire.com - April 18 at 8:00 AM
	All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy zacks.com - April 16 at 1:01 PM
	Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded by StockNews.com to Sell americanbankingnews.com - April 16 at 3:42 AM
	Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to "Sell" by StockNews.com marketbeat.com - April 15 at 11:09 PM
	Needham & Company LLC Reiterates "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) americanbankingnews.com - April 13 at 6:16 AM
	Lexicon Pharmaceuticals' (LXRX) Hold Rating Reiterated at Needham & Company LLC marketbeat.com - April 11 at 8:31 AM
	Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 5.9% marketbeat.com - April 4 at 2:03 PM
	Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference finance.yahoo.com - April 3 at 8:32 AM
	Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 3.7% marketbeat.com - April 1 at 2:58 PM
	Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 11.1% marketbeat.com - March 27 at 12:44 PM
	Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo globenewswire.com - March 25 at 9:20 AM
	LXRX Apr 2024 5.000 put finance.yahoo.com - March 16 at 7:59 PM
	Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin zacks.com - March 13 at 1:46 PM
	Path forward for sotagliflozin becomes clear after FDA feedback thepharmaletter.com - March 12 at 6:19 PM
	Lexicon Announces Positive Data Of InTandem3 Study In Type 1 Diabetes Patients With CKD; Stock Down markets.businessinsider.com - March 12 at 1:18 PM
	Lexicon stock slides 8% after rallying 30% in prior session seekingalpha.com - March 12 at 1:18 PM
	5 years after initial FDA rejection, Lexicon prepares to resubmit Type 1 diabetes hopeful Zynquista fiercepharma.com - March 12 at 8:16 AM
	New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease finance.yahoo.com - March 12 at 8:16 AM
	Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset seekingalpha.com - March 12 at 4:01 AM
	Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin marketwatch.com - March 11 at 10:53 AM
	Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA finance.yahoo.com - March 11 at 10:53 AM
	Lexicon: Q4 Earnings Snapshot washingtonpost.com - March 11 at 10:53 AM
	Lexicon Pharmaceuticals: Q4 Earnings Insights benzinga.com - March 11 at 10:53 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Allakos

NASDAQ:ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

COMPASS Pathways

NASDAQ:CMPS

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Concert Pharmaceuticals

NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Lexicon Pharmaceuticals

NASDAQ:LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial